我院2010-2012年抗肿瘤药应用分析

Analysis of the Utilization of Antineoplastic Drugs in Our Hospital during 2010-2012

目的:评价我院2010-2012年抗肿瘤药临床应用情况。方法:采用销售金额排序、用药频度(DDDs)排序等方法,对我院2010-2012年抗肿瘤药临床应用情况进行回顾性分析。结果:我院抗肿瘤药销售金额占药品总销售金额的比例呈现逐年上升趋势,其他类抗肿瘤药销售金额连续3年列第1位;紫杉醇、多西他赛作为临床一线抗肿瘤药,其2011年和2012年的销售金额均位于前3位。DDDs排序靠前的主要是铂类、中成药类抗肿瘤药及植物来源抗肿瘤药及其衍生物。结论:我院抗肿瘤药临床应用情况基本符合目前我国恶性肿瘤药治疗现状和趋势。

OBJECTIVE： To evaluate the clinical use of antineoplastic drugs in our hospital during 2010--2012. METHODS： The utilization of antineoplastic drugs in our hospital during 2010--2012 was analyzed retrospectively in terms of consumption sum and DDDs. RESULTS： The proportion of consumption sum of antineoplastic drugs in total consumption sum increased year by year; that of other types of antineoplastic drugs ranked in the first in these all three years. Consumption sum of paclitaxel and docetaxel as the first-line drugs both ranked in the top three from 2010 to 2012. The front of DDDs list was platinum, Chinese patent medicine and plant-source antitumor medicine and its derivatives. CONCLUSIONS： The clinical use of antineoplastic drugs in our hosoital is in accordance with the situation and trend of treatment of malignant tumors in China.